Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma

Xu, Xiaojing; Huang, Peixin; Tian, Hui; Chen, Yi; Ge, Ning; Tang, Wengquing; Yang, Biwei; Xia, Jinglin

doi:10.1111/jgh.12554

Cited by 25 publications

(25 citation statements)

References 29 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Xu et al reported that the level of HBV-DNA became undetectable in 45.6% of the patients treated with lamivudine in combination with TACE, while only 11.2% of the patients treated with TACE alone had a undetectable HBV-DNA, and antiviral treatment enhanced the one-, two-, and three-year survival rates from 60%, 48%, and 48% to 83%, 69%, and 58%, respectively [47]. In a randomized control study, Jang et al found that patients who received lamivudine in preemptive therapy from the start of transarterial chemo-lipiodolization have a much lower chance of viral reactivation [48].…”

Section: Antiviral Treatment In Transcatheter Arterial Chemoembolizationmentioning

confidence: 96%

The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

et al. 2016

View full text Add to dashboard Cite

Section: Antiviral Treatment In Transcatheter Arterial Chemoembolizationmentioning

confidence: 96%

The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

et al. 2016

View full text Add to dashboard Cite

“…The characteristics and quality of the studies are summarized in Table 1. Nucleotide analogs lamivudine alone was used in the study from Yoshida et al and Xu et al [16, 17]. In other studies, lamivudine, adefovir, telbivudine, and entecavir were used.…”

Section: Resultsmentioning

confidence: 99%

Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Liu

Zhao

et al. 2017

Disease Markers

View full text Add to dashboard Cite

Aim. To determine whether nucleot(s)ide analogs therapy has survival benefit for patients with HBV-related HCC after unresectable treatment. Method. A systematic search was conducted through seven electronic databases including PubMed, OVID, EMBASE, Cochrane Databases, Elsevier, Wiley Online Library, and BMJ Best Practice. All studies comparing NA combined with unresectable treatment versus unresectable treatment alone were considered for inclusion. The primary outcome was the overall survival (OS) after unresectable treatment for patients with HBV-related HCC. The secondary outcome was the progression-free survival (PFS). Results were expressed as hazard ratio (HR) for survival with 95% confidence intervals. Results. We included six studies with 994 patients: 409 patients in nucleot(s)ide analogs therapy group and 585 patients without antiviral therapy in control group. There were significant improvements for the overall survival (HR = 0.57; 95% CI = 0.47–0.70; p < 0.001) and progression-free survival (HR = 0.84; 95% CI = 0.71–0.99; p = 0.034) in the NA-treated group compared with the control group. Funnel plot showed that there was no significant publication bias in these studies. When it comes to antiviral drugs and operation method, it also showed benefit in NA-treated group. At the same time, overall mortality as well as mortality secondary to liver failure in NA-treated group was obviously lesser. Sensitivity analyses confirmed the robustness of the results. Conclusions. Nucleot(s)ide analogs therapy after unresectable treatment has potential beneficial effects in terms of overall survival and progression-free survival. NA therapy should be considered in clinical practice.

show abstract

“…These include HBeAg status, viral load, baseline liver function, age, gender, and the intensity of LRT and the use of anthracyclines [80] . However, the data for HBV reactivation following TACE remains somewhat inconclusive, with some studies suggesting increase risk, whereas other studies have demonstrated no changes, or even decline in HBV DNA after chemoembolization [81,82] . The mechanism underlying the decline in viral load remains unclear, and may be due to the natural fluctuation that is independent of the TACE, or possibly from a reduction in tumor load, which may support HBV replication or impair the host immunity.…”

Section: Antiviral Therapy For Hcc Patients Undergoing Locoregional Tmentioning

confidence: 94%

The role of oral antiviral therapy in hepatitis B-related hepatocellular carcinoma

Fung¹,

Chok²

2017

View full text Add to dashboard Cite

Hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) in places where chronic hepatitis B infection is endemic. Oral nucleos(t)ide analog (NA) therapy can reduce the risk of HCC, but cannot completely prevent its development. For HBV-related HCCs, viral inhibition by NAs can preserve or improve liver function, thereby increasing the chance of therapeutic intervention. After surgical resection, NAs can prevent reactivation of HBV, and also reduce the chance of de novo development of HCC in the remnant liver. For those who undergo liver transplantation, NAs are essential to prevent reactivation and graft hepatitis, but is not likely to prevent HCC recurrence, which is due to metastatic disease. The role of NAs for non-curable advanced HCC is less well defined. These include patients undergoing locoregional therapy, chemotherapy, or palliation. Although antiviral therapy can preserve liver function, which may be compromised by HBV, it is unable to prevent disease progression from HCC. At the time of HCC diagnosis, most patients will already be receiving NAs, and these patients should be maintained on therapy. For patients not on antiviral therapy at the time of HCC diagnosis, the decision to commence therapy is often determined by the stage of HCC and life expectancy. Patients undergoing curative therapy, or locoregional therapy/chemotherapy with reasonable life expectancy, should be commenced on antiviral therapy. Key words:Antiviral therapy, hepatitis B virus, hepatocellular carcinoma ABSTRACTArticle history:

show abstract

Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma

Abstract: Lamivudine therapy could reduce HBV activation and improve survival of HCC patients treated with TACE. Lamivudine therapy and AFP level are two independent factors affecting OS.

Cited by 25 publications

References 29 publications

The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

The role of oral antiviral therapy in hepatitis B-related hepatocellular carcinoma

Contact Info

Product

Resources

About